Shelf life (days): 1460.0
Formulation: A solid
Formal Name: (3R,5S,E)-7-(3-(4-fluorophenyl)-1-(propan-2-yl-1,1,1,3,3,3-d6)-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoate, monosodium salt
Purity: ≥95% (mixture of enantiomers)
Formula Markup: C24H19D6FNO4 / Na
Formula Weight: 439.484173
Notes: Fluvastatin-d6 is intended for use as an internal standard for the quantification of fluvastatin (Item Nos. 10010334 / 10010337) by GC- or LC-MS. Fluvastatin is an inhibitor of HMG-CoA reductase (Ki = 0.3 nM for the rat enzyme).{15309,15312} It also inhibits the human cytochrome P450 (CYP) isoform CYP2C9 (IC50 = 100 nM).{37698} Fluvastatin inhibits oxidized LDL-induced ferroptosis and reverses oxidized LDL-induced decreases in glutathione peroxidase 4 (GPX4) and system Xc- cystine-glutamate antiporter levels in human umbilical vein endothelial cells (HUVECs).{60825} In vivo, fluvastatin (2 mg/kg per day) decreases serum cholesterol, triglyceride, and phospholipid levels, the formation of thiobarbituric acid-reactive substances (TBARS), and vascular angiotensin-converting enzyme (ACE) activity in rabbits fed a high-cholesterol diet.{37699} It increases survival in a mouse model of myocardial infarction when administered at a dose of 10 mg/kg per day.{37700} Formulations containing fluvastatin have been used in the treatment of hypercholesterolemia and the prevention of cardiovascular disease.
English
Deutsch
